Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $11.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 219.77% from the […]

HC Wainwright restated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a research report report published on Tuesday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock. Several other analysts also recently commented on RGLS. Canaccord Genuity Group raised their price objective on shares […]

HC Wainwright reaffirmed their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $20.00 target price on the specialty pharmaceutical company’s stock. Other research analysts also recently issued research reports about the stock. Needham & Company […]

HC Wainwright initiated coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC – Free Report) in a research note issued to investors on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $7.00 price target on the stock. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q3 2024 earnings at ($0.13) EPS, Q4 […]